The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Compounds · Secretagogues & GH axis · continued

Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset posts 61–65

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

EK
ew.kuuselaTL2 Moderator23 Apr 2025#61
j.castellanos, post #57: Development history is more informative than speculation: ipamorelin was investigated clinically for post-operative ileus and was not taken forward to registration. That it was not brought to market tells you something about the cost-benefit calculation that any amount of forum enthusiasm does not. Go to post

I read post #59 twice before replying, because I had assumed the opposite.

Tesamorelin has an approved indication in HIV-associated lipodystrophy. That is the only compound in this class with a registration-quality evidence base from a proper trial programme. Generalising from that narrow population to healthy adults is a substantial extrapolation.

22 likes in reply to #57 15mo
B
BuchholzTL2Member27 Apr 2025#62
f.danquah, post #44: Secretagogues and glucose tolerance: there is a mechanistic concern that sustained growth hormone elevation might impair glucose tolerance. The clinical relevance of this concern in practice is not well established. Go to post

GHRH analogues versus ghrelin mimetics are often conflated but they are different mechanisms. GHRH analogues (like CJC-1295) cause the pituitary to release growth hormone. Ghrelin mimetics (like GHRPs) act on the ghrelin receptor directly. The effect on growth hormone secretion is similar but the mechanisms are distinct.

10 likes in reply to #44 15mo
GD
g.danquahTL2 Moderator30 Apr 2025#63

IGF-1 as a surrogate: it is a better integrated measure than a spot growth hormone level and it is still a surrogate, with all the caveats that come with surrogates. Stable or rising IGF-1 is not the same as "this is working" in any health-related sense.

1 like 15mo
SS
s.stavrianosTL24 May 2025#64
SP
s.perrinTL2 Moderator8 May 2025#65
v.salgado, post #54: Development history is more informative than speculation: ipamorelin was investigated clinically for post-operative ileus and was not taken forward to registration. That it was not brought to market tells you something about the cost-benefit calculation that any amount of forum enthusiasm does not. Go to post

Coming back to post #63, because the follow-up matters more than the original answer.

Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing standards than most.

16 likes in reply to #54 15mo

Suggested topics

TopicParticipantsRepliesViewsActivity
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…
BNGRKRZSHM+9 13 249 17mo
Secretagogues and glucose tolerance: the mechanistic concern — what changed since
Secretagogues and glucose tolerance: the mechanistic concern — what changed since Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021)…
TLDKAIEF+2 6 31k 2mo
Secretagogues and glucose tolerance: the mechanistic concern
On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
INRDMDOVFF+64 70 52k 17d
Why this subcategory is stricter about sourcing than most
Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
DOCAEFRESC+48 52 617 21d
IGF-1 as a surrogate endpoint and its limitations — the long version
On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do…
NOMGCRKBGP+14 18 53k 12mo

Related topics — sharing the tags GHRP class, ipamorelin, tesamorelin

TopicParticipantsRepliesViewsActivity
Revisiting: What a well-designed human trial of a secretagogue would look like
On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it…
HBSBOIDAS+69 74 25k 18mo
Secretagogues and glucose tolerance: the mechanistic concern
On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
INRDMDOVFF+64 70 52k 17d
Why pulsatile secretion matters for interpreting secretagogue claims
Why pulsatile secretion matters for interpreting secretagogue claims — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited…
RBVOFJCN+5 9 1.6k 15h
Reading a rodent study on a secretagogue without over-extrapolating — the long version
Reading a rodent study on a secretagogue without over-extrapolating — the long version — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…
CDDBANKBMA+59 66 30k 4h
Why this subcategory is stricter about sourcing than most
Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
DOCAEFRESC+48 52 617 21d